Severe local tissue necrosis can occur if there is extravasation during administration. It should never be given IM or subcutaneously. This drug should be given slowly into a freely flowing IV infusion.In patients with hepatic impairment, a dose reduction should be considered.Īdministration of the second course should be delayed in patients who experience severe mucositis, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended.In patients with renal impairment, a dose reduction should be considered.Use: For the treatment of acute myeloid leukemia (AML) in combination with other approved antileukemic drug (including French-American-British classifications M1 through M7) Renal Dose Adjustments Use: For the treatment of acute myeloid leukemia (AML) in combination with other approved antileukemic drug (including French-American-British classifications M1 through M7) Usual Adult Dose for Acute Nonlymphocytic Leukemia Administration of the second course should be delayed in patients who experience severe mucositis until recovery has occurred, and a dose reduction of 25% is recommended.In patients with unequivocal evidence of leukemia after the first induction course, a second course may be administered. Maximum recommended cumulative lifetime dose for the IV formulation: 150 mg/m2 ![]() Usual Adult Dose for Acute Myeloid Leukemiaġ2 mg/m2 daily for 3 days by slow (10 to 15 min) IV administration in combination with cytarabine
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |